

ASTRAZENECA PLC  
Form 6-K  
June 25, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of June 2015

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

Publication of Prospectus

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Base Prospectus for the AstraZeneca PLC U.S. \$5,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

The last drawdown under the EMTN programme was in 2014.

To view the full document, please paste the following URL into the address bar of your browser.

[http://www.rns-pdf.londonstockexchange.com/rns/2151R\\_-2015-6-25.pdf](http://www.rns-pdf.londonstockexchange.com/rns/2151R_-2015-6-25.pdf)

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

<http://www.morningstar.co.uk/uk/NSM>

A C N Kemp  
Company Secretary  
25 June 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 25 June 2015

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary